Xenocor, Inc., an emerging leader in developing a new, revolutionary medical imaging platform that provides the most cost‐effective high definition laparoscopy solutions, announced that its first product, the Xenoscope, was 510(k) cleared by the U.S. FDA for marketing and distribution. The Xenoscope is the first single-use disposable laparoscope that will be offered in a sterile condition.
“We are very pleased to receive this fast-track clearance of our product,” said Ashok C. Khandkar, Ph.D., chief executive officer of Xenocor. “This clearance allows us to bring products to world-wide markets with superior imaging characteristics while reducing the cost of care.”
“Xenocor’s patent-pending technology not only enables me to have superior diagnostic imaging, but also address the risk of hospital acquired infections that are of particular concern for patients, doctors and hospitals,” commented John Langell, M.D., a co-founder who also serves as the vice dean for innovation, University of Utah School of Medicine, executive director, Center for Medical Innovation, University of Utah and co-director of its Global Health Institute. “I am especially pleased to note the lower cost of care which can be of lasting value and make an important difference in the lives of patients and healthcare globally.”
About Xenocor, Inc.
Xenocor, Inc. is a private medical device company focused on developing and commercializing the innovative laparoscopy devices. Xenocor’s products provide clinically relevant high definition imaging to physicians performing minimally invasive laparoscopic procedures. Xenocor has assembled a management team and board of directors with significant clinical and commercial development experience and collaborates with clinical advisors globally. Xenocor, Inc. is located in Salt Lake City, UT. For more information: www.xenocor.com.
(Source: PR Newswire)
